GH Research

Yahoo Finance • last month

Jefferies analyst says Trump's executive order on psychedelics is an 'official stamp of validation' for investors

Psychedelic drugmakers just got a jolt that Wall Street couldn't ignore. After President Donald Trump signed an executive order (1) aimed at fast-tracking research and access to psychedelic therapies as a form of mental-health treatment, i... Full story

Yahoo Finance • last month

Marvell–Google AI talks, Trump EO boosts psychedelic stocks

Yahoo Finance's Julie Hyman and Brooke DiPalma takes a closer look at some of Monday morning's trending tickers and stories. Marvell (MRVL) stock is surging on reports that the company is in talks with Google (GOOG, GOOGL) to develop arti... Full story

Yahoo Finance • last month

Trump issues executive order on psychedelic drugs

[President Trump Signs Executive Order At The White House] Tasos Katopodis/Getty Images News President Donald Trump on Saturday signed an executive order to expedite access to research and treatments ​based on psychedelic drugs, a move th... Full story

Yahoo Finance • last month

Trump Trade: President to sign order on psychedelic used for PTSD

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly. Claim 30% Off TipRanks Unlock hed... Full story

Yahoo Finance • 8 months ago

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • 10 months ago

GH Research GAAP EPS of -$0.15

* GH Research press release [https://seekingalpha.com/pr/20192823-gh-research-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:GHRS [https://seekingalpha.com/symbol/GHRS]): Q2 GAAP EPS of -$0.15. * C... Full story

Yahoo Finance • 10 months ago

GH Research reports progress on FDA engagement for GH001 IND

DUBLIN - GH Research PLC (NASDAQ:GHRS), a $1.04 billion market cap biotech company that has seen its stock surge 90% over the past six months, reported Wednesday that it continues to engage with the U.S. Food and Drug Administration regard... Full story

Yahoo Finance • 10 months ago

GH Research Announces Global Pivotal Program Plans and Further Development Updates

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment was well tolerated and no... Full story

Yahoo Finance • 11 months ago

GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule

GH Research (NASDAQ:GHRS) is one of the best-performing NASDAQ stocks according to analysts. On June 20, GH Research announced that it had submitted a complete response to the US FDA regarding the clinical hold on its Investigational New D... Full story

Yahoo Finance • 11 months ago

GH Research submits response to FDA clinical hold for depression drug

DUBLIN - GH Research PLC (NASDAQ:GHRS), a $752 million market cap biotech company whose shares have surged 73% over the past six months, announced Friday it has submitted its complete response to the U.S. Food and Drug Administration regar... Full story

Yahoo Finance • 11 months ago

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • last year

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in... Full story

Yahoo Finance • last year

GH Research Announces Pricing of $150 Million Public Offering

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • last year

GH Research Announces Proposed Public Offering

DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • last year

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with... Full story

Yahoo Finance • last year

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a c... Full story

Yahoo Finance • 2 years ago

15 Best Falling Stocks To Buy Now

In this article, we will take a detailed look at the15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Falling Stocks To Buy Now. The Wall Street is headed to end 2023 on a strongly positive not... Full story

Yahoo Finance • 3 years ago

GH Research Reports Third Quarter Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial res... Full story

Yahoo Finance • 3 years ago

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and... Full story

Yahoo Finance • 3 years ago

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial res... Full story